Cannabis and the brain

Brain

Volumn 126, Issue 6, 2003, Pages 1252-1270

  Iversen, Leslie ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

2 arachidonylglycerol; Anandamide; Cannabinoid CB1 receptor; Rimonabant (SR141716A); 9 tetrahydrocannabinol

Indexed keywords

2 ARACHIDONOYLGLYCEROL; 2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; AMINO ACID; ANANDAMIDE; ANTIEMETIC AGENT; CANNABINOID; CANNABINOID 1 RECEPTOR; CANNABIS; CHOLECYSTOKININ; DRONABINOL; LIPID; NEUROPEPTIDE; NEUROTRANSMITTER; RIMONABANT;

APPETITE; BIOSYNTHESIS; BRAIN; BRAIN REGION; CANNABIS ADDICTION; DEPOLARIZATION; DRUG EFFECT; GABAERGIC SYSTEM; HIPPOCAMPUS; HUMAN; INTERNEURON; MEMORY; MENTAL DISEASE; MULTIPLE SCLEROSIS; MUSCLE SPASM; NEOCORTEX; NEUROANATOMY; NEUROPATHOLOGY; NEUROTOXICITY; NEUROTRANSMITTER RELEASE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PSYCHOMOTOR ACTIVITY; RECEPTOR DENSITY; REVIEW; SYNAPSE; VOMITING;

EID: 0038692066     PISSN: 00068950     EISSN: None     Source Type: Journal    
DOI: 10.1093/brain/awg143     Document Type: Review

References (196)

1. Abel EL. Marihuana and memory: acquisition or retrieval? Science 1971; 173: 1038-41.
2. Abood ME, Martin BR. Neurobiology of marijuana abuse. [Review]. Trends Pharmacol Sci 1992; 13: 201-6.
3. Aceto MD, Scates SM, Lowe JA, et al. Dependence on delta 9-tetrahydrocannabinol: studies on precipitated and abrupt withdrawal. J Pharmacol Exp Ther 1996; 278: 1290-5.
4. Aceto MD, Scates SM, Martin BR. Spontaneous and precipitated withdrawal with a synthetic cannabinoid, WIN 55212-2. Eur J Pharmacol 2001; 416: 75-81.
5. Adams IB, Martin BR. Cannabis: pharmacology and toxicology in animals and humans. [Review]. Addiction 1996; 91: 1585-14.
6. A-receptor synapses in the mammalian CNS. [Review]. Trends Neurosci 1995; 18: 333-40.
7. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. DSM-IV. 4th ed. Washington (DC): American Psychiatric Association; 1994.
8. Andreasson S, Allebeck P, Engstrom A, et al. Cannabis and schizophrenia. A longitudinal study of Swedish conscripts. Lancet 1987; 2: 1483-5.
9. Andreasson S, Allebeck P, Rydberg U. Schizophrenia in users and nonusers of cannabis. Acta Psychiatr Scand 1989; 79: 505-10.
10. Anthony JC, Warner LA, Kessler RC. Comparative epidemiology of dependence on tobacco, alcohol, controlled substances and inhalants. Basic findings from the National Comorbidity Survey. Exp Clin Psychopharmacol 1994; 2: 244-68.
11. Arseneault L, Cannon M, Poulton R, et al. Cannabis use in adolescence and risk for adult psychosis: longitudinal prospective study. BMJ 2002; 325: 1212-3.
12. Atha MJ, Blanchard S. Regular users. Self-reported drug consumption patterns and attitudes towards drugs among 1333 regular cannabis users. Wigan: Independent Drug Monitoring Unit; 1997.
13. Baker D, Pryce G, Croxford JL, et al. Cannabinoids control spasticity and tremor in a multiple sclerosis model. Nature 2000; 404: 84-7.
14. Beal JA, Olson R, Laubenstein L, et al. Dronabinol as a treatment for anorexia associated with weight loss in patients with AIDS. J Pain Symptom Manage 1995; 10: 89-97.
15. Bisogno T, Berrendero F, Ambrosino G, et al. Brain regional distribution of endocannabinoids: implications for their biosynthesis and biological function. Biochem Biophys Res Commun 1999; 256: 377-80.
16. Block RI, O'Leary DS, Ehrhardt JC, et al. Effects of frequent marijuana use on brain tissue volume and composition. Neuroreport 2000; 11: 491-6.
17. 1 receptors. Neuroscience 2000; 95: 5-7.
18. Bowman M, Pihl RO. Cannabis: psychological effects of chronic heavy use. A controlled study of intellectual functioning in chronic users of high potency cannabis. Psychopharmacologia 1973; 29: 159-70.
19. Breivogel CS, Childers SR. The functional neuroanatomy of brain cannabinoid receptors. [Review]. Neurobiol Dis 1998; 5: 417-31.
20. Breivogel CS, Griffin G, Di Marzo V, et al. Evidence for a new G protein-coupled cannabinoid receptor in mouse brain. Mol Pharmacol 2001; 60: 155-63.
21. British Medical Association. Therapeutic uses of cannabis. [Review]. Amsterdam: Harwood Academic; 1997.
22. Budney AJ, Hughes JR, Moore BA, et al. Marijuana abstinence effects in marijuana smokers maintained in their home environment. Arch Gen Psychiatry 2001; 58: 917-24.
23. Cadas H, di Tomaso E, Piomelli D. Occurrence and biosynthesis of endogenous cannabinoid precursors, N-arachidonoyl phosphatidylethanolamine, in rat brain. J Neurosci 1997; 17: 1226-42.
24. Campbell FA, Tramer MR, Carroll D, et al. Are cannabinoids an effective and safe treatment option in the management of pain? A qualitative systematic review. [Review]. BMJ 2001; 323: 13-6.
25. Caulfield MP, Brown DA. Cannabinoid receptor agonists inhibit Ca current in NG108-15 neuroblastoma cells via a pertussis toxinsensitive mechanism. Br J Pharmacol 1992; 106: 231-2.
26. Chan PC, Sills RC, Braun AG, et al. Toxicity and carcinogenicity of delta 9-tetrahydrocannabinol in Fischer rats and B6C3F1 mice. Fundam Appl Toxicol 1996; 30: 109-17.
27. Chan GCK, Hinds TR, Impey S, et al. Hippocampal neurotoxicity of delta 9-tetrahydrocannabinol. J Neurosci 1998; 18: 5322-32.
28. Colombo G, Agabio R, Diaz G, et al. Appetite suppression and weight loss after the cannabinoid antagonist SR141716. Life Sci 1998; 63: PL113-7.
29. Compton DR, Aceto MD, Lowe J, et al. In vivo characterization of a specific cannabinoid receptor antagonist (SR141716A): inhibition of delta 9-tetrahydocannabinol-induced responses and apparent agonist activity. J Pharmacol Exp Ther 1996; 277: 586-94.
30. Consroe P, Musty R, Rein J, et al. The perceived effects of smoked cannabis on patients with multiple sclerosis. Eur Neurol 1996; 38: 44-8.
31. Cravatt BF, Demarest K, Patricelli MP, et al. Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase. Proc Natl Acad Sci USA 2001; 98: 9371-6.
32. 1 receptor antagonist/inverse agonist SR141716A. Neuropsychopharmacology 2001; 24: 198-203.
33. Darmani NA. The potent emetogenic effects of the endocannabinoid, 2-AG (2-arachidonylglycerol) are blocked by delta 9-tetrahydrocannabinol and other cannabinoids. J Pharmacol Exp Ther 2002; 300: 34-42.
34. Deadwyler SA, Hampson RE, Childers SR. Functional significance of cannabinoid receptors in brain. In: Pertwee RG, editor. Cannabinoid receptors. London: Academic Press; 1995. p. 206-31.
35. 1 receptor in mice. Pharmacol Biochem Behav 2001; 69: 251-9.
36. Devane WA, Hanus L, Breuer A, et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 1992; 258: 1946-9.
37. Diana M, Melis M, Muntoni AL, et al. Mesolimbic dopaminergic decline after cannabinoid withdrawal. Proc Natl Acad Sci USA 1998; 95: 10269-73.
38. DiMarzo V, Fontana A, Cadas H, et al. Formation and inactivation of endogenous cannabinoid anandamide in central neurons. Nature 1994; 372: 686-91.
39. 2 receptor-mediated actions of anandamide in mouse brain. J Neurochem 2000; 75: 2434-44.
40. DiMarzo V, Goparaju SK, Wang L, et al. Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature 2001a; 410: 822-5.
41. DiMarzo V, Bisogno T, De Petrocellis L. Anandamide: some like it hot. [Review]. Trends Pharmacol Sci 2001b; 22: 346-9.
42. Dixon WE. The pharmacology of cannabis indica. BMJ 1899; 2: 1354-7.
43. Dornbush RL, Freedman AM, Fink M, editors. Chronic cannabis use. [Review]. Ann NY Acad Sci 1976; 282: 1-430.
44. 1 receptor. Neuroreport 2001; 12: 3973-8.
45. D'Souza DC, Kosten TR. Cannabinoid antagonists. [Review]. Arch Gen Psychiatry 2001; 58: 330-1.
46. Earleywine M. Understanding marijuana. [Review]. Oxford: Oxford University Press; 2002.
47. 1. J Comp Neurol 2000; 422: 159-71.
48. 1 receptor in rat brain. Proc R Soc Lond B Biol Sci 1998; 265: 2081-5.
49. Elphick MR, Egertová M. The neurobiology and evolution of cannabinoid signalling. [Review]. Philos Trans R Soc Lond B Biol Sci 2001; 356: 381-408.
50. Emrich HM, Leweke FM, Schneider U. Towards a cannabinoid hypothesis of schizophrenia: cognitive impairments due to dysregulation of the endogenous cannabinoid system. [Review]. Pharmacol Biochem Behav 1997; 56: 803-7.
51. Felder CC, Glass M. Cannabinoid receptors and their endogenous agonists. [Review]. Annu Rev Pharmacol Toxicol 1998; 38: 179-200.
52. Felder CC, Nielsen A, Briley EM, et al. Isolation and measurement of the endogenous cannabinoid receptor agonist, anandamide, in brain and peripheral tissues of human and rat. FEBS Lett 1996; 393: 231-5.
53. Fergusson DM, Horwood LJ, Swain-Campbell NR. Cannabis dependence and psychotic symptoms in young people. Psychol Med 2003; 33: 15-21.
54. Fox A, Kesingland A, Gentry C, et al. The role of central and peripheral cannabinoid 1 receptors in the antihyperalgesic activity of cannabinoids in a model of neuropathic pain. Pain 2001; 92: 91-100.
55. French ED, Dillon K, Wu X. Cannabinoids excite dopamine neurons in the ventral tegmentum and substantia nigra. Neuroreport 1997; 8: 649-52.
56. Fride E, Ginzburg Y, Breuer A, et al. Critical role of the endogenous cannabinoid system in mouse pup suckling and growth. Eur J Pharmacol 2001; 419: 207-14.
57. Fuentes JA, Ruiz-Gayo M, Manzanares J, et al. Cannabinoids as potential new analgesics. Life Sci 1999; 65: 675-85.
58. Galve-Roperh I, Sanchez C, Cortés ML, et al. Anti-tumoral action of cannabinoids: involvement of sustained ceramide accumulation and extracellular signal-regulated kinase activation. Nat Med 2000; 6: 313-9.
59. Gill EW, Paton WDM, Pertwee RG. Preliminary experiments on the chemistry and pharmacology of cannabis. Nature 1970; 229: 134-6.
60. Giuffrida A, Piomelli D. The endocannabinoid system: a physiological perspective on its role in psychomotor control. [Review]. Chem Phys Lipids 2000; 108: 151-8.
61. Giuffrida A, Parsons LH, Kerr TM, et al. Dopamine activation of endogenous cannabinoid signaling in dorsal striatum. Nat Neurosci 1999; 2: 358-63.
62. Giuffrida A, Désarnaud F, Piomelli D. Endogenous cannabinoid signaling and psychomotor disorders. Prostaglandins Other Lipid Mediat 2000; 61: 63-70.
63. Giuffrida A, Beltramo M, Piomelli D. Mechanisms of endocannabinoid inactivation: biochemistry and pharmacology. [Review]. J Pharmacol Exp Ther 2001; 298: 7-14.
64. Greenberg HS, Werness SAS, Pugh JE, et al. Short-term effects of smoking marijuana on balance in patients with multiple sclerosis and normal volunteers. Clin Pharmacol Ther 1994; 55: 324-8.
65. Guzmén M, Sánchez C, Galve-Roperh I. Control of the cell survival/death decision by cannabinoids. [Review]. J Mol Med 2001; 78: 613-25.
66. Hájos N, Katona I, Naiem SS, et al. Cannabinoids inhibit hippocampal GABAergic transmission and network oscillations. Eur J Neurosci 2000; 12: 3239-49.
67. Hájos N, Ledent C, Freund TF. Novel cannabinoid-sensitive receptor mediates inhibition of glutamatergic synaptic transmission in the hippocampus. Neuroscience 2001; 106: 1-4.
68. Hall W, Degenhardt L. Cannabis use and psychosis: a review of clinical and epidemiological evidence. Aust NZ J Psychiatry 2000; 34: 26-34.
69. Hambrecht M, Hafner H. Cannabis, vulnerability, and the onset of schizophrenia: an epidemiological perspective. Aust NZ J Psychiatry 2000; 34: 468-75.
70. Hampson RE, Deadwyler SA. Cannabinoids, hippocampal function and memory. [Review]. Life Sci 1999; 65: 715-23.
71. Hampson RE, Deadwyler SA. Cannabinoids reveal the necessity of hippocampal neural encoding for short-term memory in rats. J Neurosci 2000; 20: 8932-42.
72. Hampson AJ, Grimaldi M, Axelrod J, et al. Cannabidiol and (-)delta 9-tetrahydrocannabinol are neuroprotective antioxidants. Proc Natl Acad Sci USA 1998; 95: 8268-73.
73. Han CJ, Robinson JK. Cannabinoid modulation of time estimation in the rat. Behav Neurosci 2001; 115: 243-6.
74. 1 receptor. Proc Natl Acad Sci USA 2001; 98: 3662-5.
75. Harper JW, Heath RG, Myers WA. Effects of cannabis sativa on ultrastructure of the synapse in monkey brain. J Neurosci Res 1977; 3: 87-93.
76. Heath RG, Fitzjarrell AT, Fontana CJ, et al. Cannabis sativa: effects on brain function and ultrastructure in rhesus monkeys. Biol Psychiatry 1980; 15: 657-90.
77. Herkenham M, Lynn AB, Johnson MR, et al. Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study. J Neurosci 1991; 11: 563-83.
78. Herzberg U, Eliav E, Bennett GJ, et al. The analgesic effects of R(+)-WIN55,212-2 mesylate, a high affinity cannabinoid agonist, in a rat model of neuropathic pain. Neurosci Lett 1997; 221: 157-60.
79. Hicks RE, Gualtieri CT, Mayo JP Jr, Perez-Reyes M. Cannabis, atropine, and temporal information processing. Neuropsychobiology 1984; 12: 229-37.
80. Hine B, Friedman E, Torrelio M, et al. Morphine-dependent rats: blockade of precipitated abstinence by tetrahydrocannabinol. Science 1975; 187: 443-5.
81. A synaptic transmission in the hippocampus. J Neurosci 2000; 20: 2470-9.
82. Hollister LE. Hunger and appetite after single doses of marihuana, alcohol, and dextroamphetamine. Clin Pharmacol Ther 1971; 12: 44-9.
83. Hollister LE. Health aspects of cannabis. [Review]. Pharmacol Rev 1986; 38: 1-20.
84. Hollister LE. Health aspects of cannabis: revisited. Int J Neuropsychopharmacol 1998; 1: 71-80.
85. Howlett AC, Johnson MR, Melvin LS, et al. Nonclassical cannabinoid analgetics inhibit adenylate cyclase: development of a cannabinoid receptor model. Mol Pharmacol 1988; 33: 297-302.
86. 1-selective cannabinoid receptor antagonist SR141716. Arch Gen Psychiatry 2001; 58: 322-8.
87. Iversen LL. The science of marijuana. [Review]. Oxford: Oxford University Press; 2000.
88. Iversen LL, Chapman V. Cannabinoids: a real prospect for pain relief? [Review]. Curr Opin Pharmacol 2002; 2: 50-5.
89. Johns A. Psychiatric effects of cannabis. [Review]. Br J Psychiatry 2001; 178: 116-22.
90. Jones RT. Marihuana: human effects. [Review] In: Iversen LL, Iversen SD, Snyder SH, editors. Handbook of psychopharmacology. Vol. 12. New York: Plenum Press; 1978. p. 373-412.
91. Jones RT. Drug of abuse profile: cannabis. [Review]. Clin Chem 1987; 33 (11 Suppl): 72B-81B.
92. Joy JE, Watson SJ, Benson JA, editors. Marijuana and medicine, assessing the science base. Washington (DC): National Academy Press; 1999.
93. 1 cannabinoid receptors regulate GABA release from axon terminals of specific hippocampal interneurons intemeurons. J Neurosci 1999; 19: 4544-58.
94. Katona I, Sperlagh B, Maglóczky Z, et al. GABAergic interneurons are the targets of cannabinoid actions in the human hippocampus. Neuroscience 2000; 100: 797-804.
95. 1 cannabinoid receptors in the amygdala and their role in the control of GABAergic transmission. J Neurosci 2001; 21: 9506-18.
96. Kaymakçalan S, Ayhan IH, Tulunay FC. Naloxone-induced or postwithdrawal abstinence signs in delta 9-tetrahydrocannabinol-tolerant rats. Psychopharmacology (Berl) 1977; 55: 243-9.
97. Koch JE. Delta 9-THC stimulates food intake in Lewis rats. Effects on chow, high-fat and sweet high-fat diets. Pharmacol Biochem Behav 2001; 68: 539-43.
98. Kreitzer AC, Regehr WG. Retrograde inhibition of presynaptic calcium influx by endogenous cannabinoids at excitatory synapses onto Purkinje cells. Neuron 2001a; 29: 717-27.
99. Kreitzer AC, Regehr WG. Cerebellar depolarization-induced suppression of inhibition is mediated by endogenous cannabinoids. J Neurosci 2001b; 21: RC174-9.
100. Landfield PW, Cadwallader LB, Vinsant S. Quantitative changes in hippocampal structure following long-term exposure to delta 9-tetrahydrocannabinol: possible mediation by glucocorticoid systems. Brain Res 1988; 443: 47-62.
101. Lawston J, Borella A, Robinson JK, et al. Changes in hippocampal morphology following chronic treatment with the synthetic cannabinoid WIN 55,212-2. Brain Res 2000; 877: 407-10.
102. 1 receptor knockout mice. Science 1999; 283: 401-4.
103. Lenz RA, Wagner JJ, Alger BE. N- and L-type calcium channel involvement in depolarization-induced suppression of inhibition in rat hippocampal CA1 cells. J Physiol 1998; 512: 61-73.
104. Lepore M, Vorel SR, Lowinson J, et al. Conditioned place preference induced by delta 9-tetrahydrocannabinol: comparison with cocaine, morphine and food reward. Life Sci 1995; 56: 2073-80.
105. Lichtman AH, Martin BR. Delta 9-tetrahydrocannabinol impairs spatial memory through a cannabinoid receptor mechanism. Psychopharmacology (Berl) 1996; 126: 125-31.
106. Lichtman AH, Fisher J, Martin BR. Precipitated cannabinoid withdrawal is reversed by delta 9-tetrahydrocannabinol or clonidine. Pharmacol Biochem Behav 2001a; 69: 181-8.
107. Lichtman AH, Sheikh SM, Loh HH, et al. Opioid and cannabinoid modulation of precipitated withdrawal in delta 9-tetrahydrocannabinol and morphine-dependent mice. J Pharmacol Exp Ther 2001b; 298: 1007-14.
108. Linzen DH, Dingemans PM, Lenior ME. Cannabis abuse and the course of recent-onset schizophrenic disorders. Arch Gen Psychiatry 1994; 51: 273-9.
109. MacKie K, Hille B. Cannabinoids inhibit N-type calcium channels in neuroblastoma-glioma cells. Proc Natl Acad Sci USA 1992; 89: 3825-9.
110. Maejima T, Hashimoto K, Yoshida T, et al. Presynaptic inhibition caused by retrograde signal from metabotropic glutamate to cannabinoid receptors. Neuron 2001; 31: 463-75.
111. 1 receptor antagonist SR141716A attenuates the memory impairment produced by delta 9-tetrahydrocannabinol or anandamide. Psychopharmacology (Berl) 1998; 140: 11-9.
112. Manno JE, Kiplinger GF, Haine SE, et al. Comparative effects of smoking marihuana or placebo on human motor and mental performance. Clin Pharmacol Ther 1970; 11: 808-15.
113. Manzanares J, Corchero J, Romero J, et al. Pharmacological and biochemical interactions between opioids and cannabinoids. Trends Pharmacol Sci 1999; 20: 287-94.
114. 1 in distinct neuronal subpopulations in the adult mouse forebrain. Eur J Neurosci 1999; 11: 4213-4225.
115. Mathers DC, Ghodse AH. Cannabis and psychotic illness. Br J Psychiatry 1992; 161: 648-53.
116. Mathew RJ, Wilson WH, Coleman RE, et al. Marijuana intoxication and brain activation in marijuana smokers. Life Sci 1997; 60: 2075-89.
117. Mathew RJ, Wilson WH, Turkington TG, et al. Cerebellar activity and disturbed time sense after THC. Brain Res 1998; 797: 183-9.
118. Matsuda LA, Lolait SJ, Brownstein MJ, et al. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 1990; 346: 561-4.
119. Mattes RD, Engelman K, Shaw LM, et al. Cannabinoids and appetite stimulation. [Review]. Pharmacol Biochem Behav 1994; 49: 187-95.
120. Mechoulam R. Marihuana chemistry. [Review]. Science 1970; 168: 1159-66.
121. Mechoulam R, Fride E. Physiology. A hunger for cannabinoids. [Review]. Nature 2001; 410: 763, 765.
122. Mechoulam R, Ben-Shabat S, Hanuš L, et al. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol 1995; 50: 83-90.
123. Mechoulam R, Fride E, Hanus L, et al. Anandamide may mediate sleep induction. [Review]. Nature 1997; 389: 25-6.
124. Mendelson JH, Babor TF, Kuehnle JC, et al. Behavioral and biologic aspects of marijuana use. [Review]. Ann NY Acad Sci 1976; 282: 186-210.
125. Meng ID, Manning BH, Martin WJ, et al. An analgesia circuit activated by cannabinoids. Nature 1998; 395: 381-3.
126. Miller LL, Branconnier RJ. Cannabis: effects on memory and the cholinergic limbic system. Psychol Bull 1983; 93: 441-56.
127. Misner DL, Sullivan JM. Mechanism of cannabinoid effects on long-term potentiation and depression in hippocampal CA1 neurons. J Neurosci 1999; 19: 6795-805.
128. Morral AR, McCaffrey DF, Paddock SM. Reassessing the marijuana gateway effect. Addiction 2002; 97: 1493-504.
129. Munro S, Thomas KL, Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature 1993; 365: 61-5.
130. Nagayama T, Sinor AD, Simon RP, et al. Cannabinoids and neuroprotection in global and focal cerebral ischemia and in neuronal cultures. J Neurosci 1999; 19: 2987-95.
131. Nakamura-Palacios EM, Winsauer PJ, Moerschbaecher JM. Effects of the cannabinoid ligand SR141716A alone or in combination with delta-9-tetrahydrocannabinol or scopolamine on learning in squirrel monkeys. Behav Pharmacol 2000; 11: 377-86.
132. Negrete JC, Knapp WP, Douglas DE, et al. Cannabis affects the severity of schizophrenic symptoms: results of a clinical survey. Psychol Med 1986; 16: 515-20.
133. Ohno-Shosaku T, Maejima T, Kano M. Endogenous cannabinoids mediate retrograde signals from depolarized postsynaptic neurons to presynaptic terminals. Neuron 2001; 29: 729-38.
134. Panikashvili D, Simeonidou C, Ben-Shabat S, et al. An endogenous cannabinoid (2-AG) is neuroprotective after brain injury. Nature 2001; 413: 527-31.
135. 1 receptor agonists produce cerebellar dysfunction in mice. J Pharmacol Exp Ther 2001; 297: 629-37.
136. Patton GC, Coffey C, Carlin JB, et al. Cannabis use and mental health in young people: cohort study. BMJ 2002; 325: 1195-8.
137. Peralta V, Cuesta MJ. Influence of cannabis abuse on schizophrenic psychopathology. Acta Psychiatr Scand 1992; 85: 127-30.
138. Pertwee RG. Tolerance to and dependence on psychotropic cannabinoids. [Review]. In: Pratt J, editor. The biological basis of drug tolerance and dependence. London: Academic Press; 1991. p. 232-65.
139. Pertwee RG. Pharmacology of cannabinoid receptor ligands. [Review]. Curr Med Chem 1999; 6: 635-64.
140. Pertwee RG. Cannabinoid receptors and pain. [Review]. Prog Neurobiol 2001; 63: 569-611.
141. Pettit DAD, Harrison MP, Olson JM, et al. Immunohistochemical localization of the neural cannabinoid receptor in rat brain. J Neurosci Res 1998; 51: 391-402.
142. Piomelli D, Beltramo M, Giuffrida A, et al. Endogenous cannabinoid signaling. [Review]. Neurobiol Dis 1998; 5: 462-73.
143. Piomelli D, Giuffrida A, Calignano A, et al. The endocannabinoid system as a target for therapeutic drugs. [Review]. Trends Pharmacol Sci 2000; 21: 218-24.
144. A responses in hippocampal pyramidal cells. J Neurosci 1992; 12: 4122-32.
145. Pitler TA, Alger BE. Depolarization-induced suppression of GABAergic inhibition in rat hippocampal pyramidal cells: G protein involvement in a presynaptic mechanism. Neuron 1994; 13: 1447-55.
146. Pontieri FE, Monnazzi P, Scontrini A, et al. Behavioral sensitization to heroin by cannabinoid pretreatment in the rat. Eur J Pharmacol 2001; 421: R1-3.
147. Pope HG Jr, Gruber AJ, Hudson JI, et al. Neuropsychological performance in long-term cannabis users. Arch Gen Psychiatry 2001; 58: 909-15.
148. 1 receptor knock-out mice. Eur J Pharmacol 1999; 379: R1-2.
149. Rinaldi-Carmona M, Barth F, Heaulme M, et al. SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett 1994; 350: 240-4.
150. Robson P. Therapeutic aspects of cannabis and cannabinoids. [Review]. Br J Psychiatry 2001; 178: 107-15.
151. RodríguezdeFonseca F, Carrera MR, Navarro M, et al. Activation of corticotropin-releasing factor in the limbic system during cannabinoid withdrawal. Science 1997; 276: 2050-4.
152. RodríguezdeFonseca F, Del Arco I, Martín-Calderón JL, et al. Role of the endogenous cannabinoid system in the regulation of motor activity. [Review]. Neurobiol Dis 1998; 5: 483-501.
153. Roth SH. Stereospecific presynaptic inhibitory effect of delta-9-tetrahydrocannabinol on cholinergic transmission in the myenteric plexus of the guinea pig. Can J Physiol Pharmacol 1978; 56: 968-75.
154. Rubino T, Patrini G, Massi P, et al. Cannabinoid-precipitated withdrawal: a time-course study of the behavioral aspect and its correlation with cannabinoid receptors and G protein expression. J Pharmacol Exp Ther 1998; 285: 813-9.
155. Sánchez C, Galve-Roperh I, Canova C, et al. Delta 9-tetrahydrocannabinol induces apoptosis in C6 glioma cells. FEBS Lett 1998; 436: 6-10.
156. 1 cannabinoid receptor antagonist SR 141716A in rats as assessed by electroencephalographic spectral and sleep-waking cycle analysis. Life Sci 1996; 58: PL103-10.
157. Sañudo-Peña MC, Tsou K, Walker JM. Motor actions of cannabinoids in the basal ganglia output nuclei. Life Sci 1999; 65: 703-13.
158. Sañudo-Peña MC, Romero J, Seale GE, et al. Activational role of cannabinoids on movement. Eur J Pharmacol 2000; 391: 269-74.
159. Satz P, Fletcher JM, Sutker LS. Neuropsychologic, intellectual, and personality correlates of chronic marijuana use in native Costa Ricans. Ann NY Acad Sci 1976; 282: 266-306.
160. Scallet AC. Neurotoxicology of cannabis and THC: a review of chronic exposure studies in animals. [Review]. Pharmacol Biochem Behav 1991; 40: 671-6.
161. Scallet AC, Uemura E, Andrews A, et al. Morphometric studies of the rat hippocampus following chronic delta-9-tetrahydrocannabinol (THC). Brain Res 1987; 436: 193-8.
162. Schlicker E, Kathmann M. Modulation of transmitter release via presynaptic cannabinoid receptors. [Review]. Trends Pharmacol Sci 2001; 22: 565-72.
163. Shen M, Thayer SA. Cannabinoid receptor agonists protect cultured rat hippocampal neurons from excitotoxicity. Mol Pharmacol 1998; 54: 459-62.
164. Shen M, Piser TM, Seybold VS, et al. Cannabinoid receptor agonists inhibit glutamatergic synaptic transmission in rat hippocampal cultures. J Neurosci 1996; 16: 4322-34.
165. Sinor AD, Irvin SM, Greenberg DA. Endocannabinoids protect cerebral cortical neurons from in vitro ischemia in rats. Neurosci Lett 2000; 278: 157-60.
166. Skosnik PD, Spatz-Glenn L, Park S. Cannabis use is associated with schizotypy and attentional disinhibition. Schizophr Res 2001; 48: 83-92.
167. Smith FL, Cichewicz D, Martin ZL, et al. The enhancement of morphine antinociception in mice by delta-9-tetrahydrocannabinol. Pharmacol Biochem Behav 1998; 60: 559-66.
168. Solowij N. Cannabis and cognitive functioning. [Review]. Cambridge: Cambridge University Press; 1998.
169. Stella N, Piomelli D. Receptor-dependent formation of endogenous cannabinoids in cortical neurons. Eur J Pharmacol 2001; 425: 189-96.
170. Stella N, Schweitzer P, Piomelli D. A second endogenous cannabinoid that modulates long-term potentiation. Nature 1997; 388: 773-8.
171. Stiglick A, Kalant H. Residual effects of chronic cannabis treatment on behavior in mature rats. Psychopharmacology (Berl) 1985; 85: 436-9.
172. Sugiura T, Kondo S, Sukagawa A, et al. 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. Biochem Biophys Res Commun 1995; 215: 89-97.
173. Swift W, Hall W, Teesson M. Cannabis use and dependence among Australian adults: results from the National Survey of Mental Health and Wellbeing. Addiction 2001; 96: 737-48.
174. 1 opioid receptor mechanism. Science 1997; 276: 2048-50.
175. Tanda G, Munzar P, Goldberg SR. Self-administration behavior is maintained by the psychoactive ingredient of marijuana in squirrel monkeys. Nat Neurosci 2000; 3: 1073-4.
176. 1 cannabinoid receptors. Naunyn Schmiedebergs Arch Pharmacol 1995; 352: 576-9.
177. 1 cannabinoid receptor antagonist, SR141716. Psychopharmacology (Berl) 1996; 126: 165-72.
178. Thomas H. Psychiatric symptoms in cannabis users. [Review]. Br J Psychiatry 1993; 163: 141-9.
179. Thornicroft G. Cannabis and psychosis. Is there epidemiological evidence for an association? Br J Psychiatry 1990; 157: 25-33.
180. Tramèr MR, Carroll D, Campbell FA, et al. Cannabinoids for control of chemotherapy induced nausea and vomiting: quantitative systematic review. [Review]. BMJ 2001; 323: 16-21.
181. US Department of Health and Human Services. US National Household Survey of Drug Abuse. 1999. Washington DC.
182. Valverde O, Maldonado R, Valjent E, et al. Cannabinoid withdrawal syndrome is reduced in pre-proenkephalin knock-out mice. J Neurosci 2000; 15: 9284-9.
183. Valverde O, Noble F, Beslot F, et al. Delta 9-tetrahydrocannabinol releases and facilitates the effects of endogenous enkephalins: reduction in morphine withdrawal syndrome without change in rewarding effect. Eur J Neurosci 2001; 13: 1816-24.
184. VanderStelt M, Veldhuis WB, Bär PR, et al. Neuroprotection by delta-9-tetrahydrocannabinol, the main active compound in marijuana, against ouabain-induced in vivo excitotoxicity. J Neurosci 2001; 21: 6475-9.
185. Varma N, Carlson GC, Ledent C, et al. Metabotropic glutamate receptors drive the endocannabinoid system in hippocampus. J Neurosci 2001; 21: RC188-93.
186. Verdoux H, Gindre C, Sorbara F, et al. Effects of cannabis and psychosis vulnerability in daily life: an experience sampling test study. Psychol Med 2003; 33: 23-32.
187. Vincent BJ, McQuiston DJ, Einhorn LH, et al. Review of cannabinoids and their antiemetic effectiveness. [Review]. Drugs 1983; 25 Suppl 1: 52-62.
188. Walker JM, Hohmann AG, Martin WJ, et al. The neurobiology of cannabinoid analgesia. [Review]. Life Sci 1999; 65: 665-73.
189. Welch SP, Stevens DL. Antinociceptive activity of intrathecally administered cannabinoids alone, and in combination with morphine, in mice. J Pharmacol Exp Ther 1992; 262: 10-18.
190. 1) receptors. Psychopharmacology (Berl) 1999; 143: 315-7.
191. Williams JH, Wellman NA, Rawlins JNP. Cannabis use correlates with schizotypy in healthy people. Addiction 1996; 91: 869-77.
192. Wilson RI, Nicoll RA. Endogenous cannabinoids mediate retrograde signalling at hippocampal synapses. Nature 2001; 410: 588-92.
193. Yamaguchi T, Hagiwara Y, Tanaka H, et al. Endogenous cannabinoid, 2-arachidonylglycerol, attenuates naloxone-precipitated withdrawal signs in morphine-dependent mice. Brain Res 2001; 909: 121-6.
194. Zammit S, Alleback P, Andreasson S, et al. Self reported cannabis use as a risk factor for schizophrenia in Swedish conscripts of 1969: historical cohort study. BMJ 2002; 325: 1199.
195. Zimmer L, Morgan JP. Marijuana myths, marijuana facts. [Review]. New York: Lindesmith Center; 1997.
196. 1 receptor knockout mice. Proc Natl Acad Sci USA 1999; 96: 5780-5.